Novel, long-duration treatment for glaucoma
AssigneeNew York Medical College
InventorsMichal L. Schwartzman, Michael W. Dunn, Jaime L. Masferrer
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of and composition for reducing intraocular pressure. The method comprises administering to a patient requiring such reduction of intraocular pressure a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid (12(R)-HETE). The method of the present invention is particularly useful in treatment of all types of glaucoma. The method is also useful in lowering intraocular pressure in preparation for eye surgery, particularly for the removal of cataracts.
Claims11
A method for reducing intraocular pressure, which comprises administering to the eye a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid or a pharmaceutically acceptable salt or ester thereof.
A composition for the treatment of glucoma or ocular hypertension, consisting essentially of a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable vehicle.
A method for treating glaucoma or ocular hypertension which comprises administering to the eye a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid or a pharmaceutically acceptable salt or ester thereof.
Dependencies are inferred from the claim text.